Bu Qing-Ao, Bu Jian-Hua, Cui Tao, You Fa-Ping, Yuan Qing-Zhong
Department of Thyroid and Breast Surgery, Central Hospital of Shengli Oil Field, Dongying, Shandong, China.
Laizhou Maternal and Child Health Care Hospital of Shandong, Shandong, China.
Pak J Pharm Sci. 2018 Nov;31(6(Special)):2869-2872.
To investigate the efficaciousness of breast-conserving therapy in connection with neoadjuvant chemotherapy on breast cancer. 68 patients, who were confirmed going down with breast cancer and hospitalized from June 2015 and June 2017, were sampled and divided into two groups using the random digit table, i.e. the observation group (n=34) and the control group (n=34). Patients in the observation group experienced breast-conserving therapy integrated with neoadjuvant chemotherapy, but those in the control group received the radical resection of breast cancer. Patients' condition in surgery, incidence of post-surgery complications as well as patient survivals were compared and coded. In the observation group, surgical duration, intraoperative bleeding amount, length of stay in hospital and incidence rate of post-surgery complications were all lower than the patients with the similar conditions in the control group with evident distinctions in statistics (p<0.05). In the observation group, survival ratios of one-to-five-year living patients were evidently higher than those in the control group. The distinctions owned evident significance in calculations (p<0.05). In comparison of the recurrence ratio of disease and the rate of distant metastasis between the observation group (5.88% and 8.82%) and the control group (11.76% and 8.82%), differences had no statistical significance (p>0.05). Before treatment, compared with the score of life quality in the two groups, no evident distinction in statistical exists (p>0.05), however, after that, the life quality in the observation group evidently outweighs the quality in the control group, which shows the distinctions in statistics (p<0.05). Breast-conserving therapy in combination with neoadjuvant chemotherapy shows promising clinical value in ameliorating the life quality, decreasing the mortality rate and the incidence of adverse reaction, which is expected to be applied in clinical practices as a kind of safe and effective method.
探讨保乳治疗联合新辅助化疗对乳腺癌的疗效。选取2015年6月至2017年6月确诊并住院的68例乳腺癌患者,采用随机数字表法分为两组,即观察组(n = 34)和对照组(n = 34)。观察组患者接受保乳治疗联合新辅助化疗,对照组患者接受乳腺癌根治术。比较并统计两组患者的手术情况、术后并发症发生率及患者生存率。观察组患者的手术时间、术中出血量、住院时间及术后并发症发生率均低于对照组中病情相似的患者,差异有统计学意义(p < 0.05)。观察组1至5年存活患者的生存率明显高于对照组,差异有统计学意义(p < 0.05)。观察组(5.88%和8.82%)与对照组(11.76%和8.82%)疾病复发率和远处转移率比较,差异无统计学意义(p > 0.05)。治疗前,两组患者生活质量评分比较,差异无统计学意义(p > 0.05),但治疗后,观察组患者生活质量明显高于对照组,差异有统计学意义(p < 0.05)。保乳治疗联合新辅助化疗在改善生活质量、降低死亡率及不良反应发生率方面具有良好的临床价值,有望作为一种安全有效的方法应用于临床实践。